Decoy Therapeutics (DCOY) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
19 Dec, 2025Executive summary
Supplement updates the definitive proxy statement for the annual meeting adjourned to December 31, 2025.
All prior information in the proxy statement remains unchanged except as noted in this supplement.
Voting matters and shareholder proposals
Annual meeting of stockholders was initially held on December 19, 2025, and adjourned to December 31, 2025.
Board of directors and corporate governance
Alliance Advisors, LLC was engaged as an independent proxy solicitation and advisory firm.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Decoy Therapeutics
- Vote on equity plan and reverse split to support Nasdaq listing after merger.DCOY
Proxy Filing9 Jan 2026 - Key votes on equity plan and reverse split aim to secure Nasdaq listing after Decoy merger.DCOYProxy Filing29 Dec 2025
- Biopharma firm seeks to raise up to $50M for cancer drug development amid significant risks.DCOYRegistration Filing16 Dec 2025
- Shareholders will vote on director elections, executive pay, and auditor ratification at the virtual annual meeting.DCOYProxy Filing2 Dec 2025
- Key votes on a reverse stock split and major share issuance could significantly impact ownership and Nasdaq compliance.DCOYProxy Filing2 Dec 2025
- Key votes on reverse stock split and major share issuance aim to maintain Nasdaq listing and financing.DCOYProxy Filing2 Dec 2025
- Shareholders will vote on a reverse stock split and new share issuance at a virtual meeting.DCOYProxy Filing2 Dec 2025
- Stockholders will vote on a reverse split, major share issuance, and meeting adjournment.DCOYProxy Filing2 Dec 2025
- Shareholders will vote on directors, executive pay, and auditor ratification at the 2024 meeting.DCOYProxy Filing2 Dec 2025